Prion propagation and toxicity occur in vitro with two-phase kinetics specific to strain and neuronal type

Journal of Virology

Volumn 87, Issue 5, 2013, Pages 2535-2548

  Hannaoui, Samia ^a,b,c,d   Maatouk, Layal ^a,b,c,d   Privat, Nicolas ^a,b,c,d   Levavasseur, Etienne ^a,b,c,d   Faucheux, Baptiste A ^a,b,c,d   Haïka, Stéphane ^a,b,c,d  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c CNRS   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PRION PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN HOMOGENATE; CELL VIABILITY; CELLULAR DISTRIBUTION; CEREBELLAR GRANULAR NEURON; CONTROLLED STUDY; EMBRYO; FEMALE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IN VITRO STUDY; MOUSE; NERVE CELL CULTURE; NEUROTOXICITY; NEUROTROPISM; NONHUMAN; PRION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; STRIATAL NEURON; VIRUS STRAIN;

ANIMALS; ASTROCYTES; BRAIN; CELL CULTURE TECHNIQUES; CELLS, CULTURED; MICE; MICE, INBRED C57BL; NEURONS; PRIONS; PRPC PROTEINS; PRPSC PROTEINS; SCRAPIE;

EID: 84874712950     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03082-12     Document Type: Article

References (63)

1. Prusiner SB. 1998. Prions. Proc. Natl. Acad. Sci. U. S. A. 95:13363-13383.
2. Prusiner SB. 1982. Novel proteinaceous infectious particles cause scrapie. Science 216:136-144.
3. Weissmann C. 2004. The state of the prion. Nat. Rev. Microbiol. 2:861-871.
4. Bruce ME. 2003. TSE strain variation. Br. Med. Bull. 66:99-108.
5. Collinge J, Clarke AR. 2007. A general model of prion strains and their pathogenicity. Science 318:930-936.
6. Fraser H, Dickinson AG. 1973. Scrapie in mice. Agent-strain differences in the distribution and intensity of grey matter vacuolation. J. Comp. Pathol. 83:29-40.
7. Bruce ME, Boyle A, Cousens S, McConnell I, Foster J, Goldmann W, Fraser H. 2002. Strain characterization of natural sheep scrapie and comparison with BSE. J. Gen. Virol. 83:695-704.
8. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, SuttieA, McCardle L, Chree A, Hope J, Birkett C, Cousens S, Fraser H, Bostock CJ. 1997. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 389:498-501.
9. Fraser H, Bruce ME, McBride PA, Scott JR. 1989. The molecular pathology of scrapie and the biological basis of lesion targeting. Prog. Clin. Biol. Res. 317:637-644.
10. Aguzzi A, Heikenwalder M, Polymenidou M. 2007. Insights into prion strains and neurotoxicity. Nat. Rev. Mol. Cell Biol. 8:552-561.
11. Sandberg MK, Al-Doujaily H, Sharps B, Clarke AR, Collinge J. 2011. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 470:540-542.
12. Flechsig E, Shmerling D, Hegyi I, Raeber AJ, Fischer M, Cozzio A, von Mering C, Aguzzi A, Weissmann C. 2000. Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice. Neuron 27:399-408.
13. Lasmezas CI, Deslys JP, Robain O, Jaegly A, Beringue V, Peyrin JM, Fournier JG, Hauw JJ, Rossier J, Dormont D. 1997. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 275:402-405.
14. Manson JC, Jamieson E, Baybutt H, Tuzi NL, Barron R, McConnell I, Somerville R, Ironside J, Will R, Sy MS, Melton DW, Hope J, Bostock C. 1999. A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. EMBO J. 18:6855-6864.
15. Faucheux BA, Morain E, Diouron V, Brandel JP, Salomon D, Sazdovitch V, Privat N, Laplanche JL, Hauw JJ, Haik S. 2011. Quantification of surviving cerebellar granule neurones and abnormal prion protein (PrP(Sc)) deposition in sporadic Creutzfeldt-Jakob disease supports a pathogenic role for small PrP(Sc) deposits common to the various molecular subtypes. Neuropathol. Appl. Neurobiol. 37:500-512.
16. Faucheux BA, Privat N, Brandel JP, Sazdovitch V, Laplanche JL, Maurage CA, Hauw JJ, Haik S. 2009. Loss of cerebellar granule neurons is associated with punctate but not with large focal deposits of prion protein in Creutzfeldt-Jakob disease. J. Neuropathol. Exp. Neurol. 68:892-901.
17. Carimalo J, Cronier S, Petit G, Peyrin JM, Boukhtouche F, Arbez N, Lemaigre-Dubreuil Y, Brugg B, Miquel MC. 2005. Activation of the JNK-c-Jun pathway during the early phase of neuronal apoptosis induced by PrP106-126 and prion infection. Eur. J. Neurosci. 21:2311-2319.
18. Cronier S, Beringue V, Bellon A, Peyrin JM, Laude H. 2007. Prion strain-and species-dependent effects of antiprion molecules in primary neuronal cultures. J. Virol. 81:13794-13800.
19. Cronier S, Laude H, Peyrin JM. 2004. Prions can infect primary cultured neurons and astrocytes and promote neuronal cell death. Proc. Natl. Acad. Sci. U. S. A. 101:12271-12276.
20. Kim YS, Carp RI, Callahan SM, Wisniewski HM. 1987. Incubation periods and survival times for mice injected stereotaxically with three scrapie strains in different brain regions. J. Gen. Virol. 68:695-702.
21. Garcia M, Charvin D, Caboche J. 2004. Expanded huntingtin activates the c-Jun terminal kinase-c-Jun pathway prior to aggregate formation in striatal neurons in culture. Neuroscience 127:859-870.
22. Haik S, Peyrin JM, Lins L, Rosseneu MY, Brasseur R, Langeveld JP, Tagliavini F, Deslys JP, Lasmezas C, Dormont D. 2000. Neurotoxicity of the putative transmembrane domain of the prion protein. Neurobiol. Dis. 7:644-656.
23. Brandel JP, Heath CA, Head MW, Levavasseur E, Knight R, Laplanche JL, Langeveld JP, Ironside JW, Hauw JJ, Mackenzie J, Alperovitch A, Will RG, Haik S. 2009. Variant Creutzfeldt-Jakob disease in France and the United Kingdom: evidence for the same agent strain. Ann. Neurol. 65:249-256.
24. Levavasseur E, Laffont-Proust I, Morain E, Faucheux BA, Privat N, Peoc'h K, Sazdovitch V, Brandel JP, Hauw JJ, Haik S. 2008. Regulating factors of PrP glycosylation in Creutzfeldt-Jakob disease-implications for the dissemination and the diagnosis of human prion strains. PLoS One 3:e2786. doi:10.1371-journal.pone.0002786.
25. Taraboulos A, Serban D, Prusiner SB. 1990. Scrapie prion proteins accumulate in the cytoplasm of persistently infected cultured cells. J. Cell Biol. 110:2117-2132.
26. Gies E, Wilde I, Winget JM, Brack M, Rotblat B, Novoa CA, Balgi AD, Sorensen PH, Roberge M, Mayor T. 2010. Niclosamide prevents the formation of large ubiquitin-containing aggregates caused by proteasome inhibition. PLoS One 5:e14410. doi:10.1371-journal.pone.0014410.
27. Baron GS, Magalhaes AC, Prado MA, Caughey B. 2006. Mouse-adapted scrapie infection of SN56 cells: greater efficiency with microsomeassociated versus purified PrP-res. J. Virol. 80:2106-2117.
28. Bosque PJ, Prusiner SB. 2000. Cultured cell sublines highly susceptible to prion infection. J. Virol. 74:4377-4386.
29. Rubenstein R, Deng H, Race RE, Ju W, Scalici CL, Papini MC, Kascsak RJ, Carp RI. 1992. Demonstration of scrapie strain diversity in infected PC12 cells. J. Gen. Virol. 73(Part 11):3027-3031.
30. Archer F, Bachelin C, Andreoletti O, Besnard N, Perrot G, Langevin C, Le Dur A, Vilette D, Baron-Van Evercooren A, Vilotte JL, Laude H. 2004. Cultured peripheral neuroglial cells are highly permissive to sheep prion infection. J. Virol. 78:482-490.
31. Cronier S, Carimalo J, Schaeffer B, Jaumain E, Beringue V, Miquel MC, Laude H, Peyrin JM. 2012. Endogenous prion protein conversion is required for prion-induced neuritic alterations and neuronal death. FASEB J. 26:3854-3861.
32. Fournier JG, Escaig-Haye F, Grigoriev V. 2000. Ultrastructural localization of prion proteins: physiological and pathological implications. Microsc. Res. Tech. 50:76-88.
33. McKinley MP, Taraboulos A, Kenaga L, Serban D, Stieber A, DeArmond SJ, Prusiner SB, Gonatas N. 1991. Ultrastructural localization of scrapie prion proteins in cytoplasmic vesicles of infected cultured cells. Lab. Invest. 65:622-630.
34. Ayers JI, Kincaid AE, Bartz JC. 2009. Prion strain targeting independent of strain-specific neuronal tropism. J. Virol. 83:81-87.
35. Kimberlin RH, Walker CA. 1986. Pathogenesis of scrapie (strain 263K) in hamsters infected intracerebrally, intraperitoneally or intraocularly. J. Gen. Virol. 67(Part 2):255-263.
36. Scott JR, Davies D, Fraser H. 1992. Scrapie in the central nervous system: neuroanatomical spread of infection and Sinc control of pathogenesis. J. Gen. Virol. 73(Part 7):1637-1644.
37. DeArmond SJ, Sanchez H, Yehiely F, Qiu Y, Ninchak-Casey A, Daggett V, Camerino AP, Cayetano J, Rogers M, Groth D, Torchia M, Tremblay P, Scott MR, Cohen FE, Prusiner SB. 1997. Selective neuronal targeting in prion disease. Neuron 19:1337-1348.
38. Kaneko K, Zulianello L, Scott M, Cooper CM, Wallace AC, James TL, Cohen FE, Prusiner SB. 1997. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc. Natl. Acad. Sci. U. S. A. 94:10069-10074.
39. Telling GC, Scott M, Mastrianni J, Gabizon R, Torchia M, Cohen FE, DeArmond SJ, Prusiner SB. 1995. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 83:79-90.
40. Saborio GP, Soto C, Kascsak RJ, Levy E, Kascsak R, Harris DA, Frangione B. 1999. Cell-lysate conversion of prion protein into its protease-resistant isoform suggests the participation of a cellular chaperone. Biochem. Biophys. Res. Commun. 258:470-475.
41. Vana K, Zuber C, Nikles D, Weiss S. 2007. Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy. Cell. Mol. Neurobiol. 27:107-128.
42. Ben-Zaken O, Tzaban S, Tal Y, Horonchik L, Esko JD, Vlodavsky I, Taraboulos A. 2003. Cellular heparan sulfate participates in the metabolism of prions. J. Biol. Chem. 278:40041-40049.
43. Caughey B. 1994. Protease-resistant PrP accumulation and scrapie agent replication: a role for sulphated glycosaminoglycans? Biochem. Soc. Trans. 22:163-167.
44. Wong C, Xiong LW, Horiuchi M, Raymond L, Wehrly K, Chesebro B, Caughey B. 2001. Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J. 20:377-386.
45. Hundt C, Peyrin JM, Haik S, Gauczynski S, Leucht C, Rieger R, Riley ML, Deslys JP, Dormont D, Lasmezas CI, Weiss S. 2001. Identification of interaction domains of the prion protein with its 37-kDa-67-kDa laminin receptor. EMBO J. 20:5876-5886.
46. Leucht C, Simoneau S, Rey C, Vana K, Rieger R, Lasmezas CI, Weiss S. 2003. The 37 kDa-67 kDa laminin receptor is required for PrP(Sc) propagation in scrapie-infected neuronal cells. EMBO Rep. 4:290-295.
47. Deleault NR, Geoghegan JC, Nishina K, Kascsak R, Williamson RA, Supattapone S. 2005. Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. J. Biol. Chem. 280:26873-26879.
48. Deleault NR, Harris BT, Rees JR, Supattapone S. 2007. Formation of native prions from minimal components in vitro. Proc. Natl. Acad. Sci. U. S. A. 104:9741-9746.
49. Geoghegan JC, Valdes PA, Orem NR, Deleault NR, Williamson RA, Harris BT, Supattapone S. 2007. Selective incorporation of polyanionic molecules into hamster prions. J. Biol. Chem. 282:36341-36353.
50. Schatzl HM, Laszlo L, Holtzman DM, Tatzelt J, DeArmond SJ, Weiner RI, Mobley WC, Prusiner SB. 1997. A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis. J. Virol. 71: 8821-8831.
51. Vilette D. 2008. Cell models of prion infection. Vet. Res. 39:10.
52. Piccardo P, Manson JC, King D, Ghetti B, Barron RM. 2007. Accumulation of prion protein in the brain that is not associated with transmissible disease. Proc. Natl. Acad. Sci. U. S. A. 104:4712-4717.
53. Ghaemmaghami S, Phuan PW, Perkins B, Ullman J, May BC, Cohen FE, Prusiner SB. 2007. Cell division modulates prion accumulation in cultured cells. Proc. Natl. Acad. Sci. U. S. A. 104:17971-17976.
54. Schultz J, Schwarz A, Neidhold S, Burwinkel M, Riemer C, Simon D, Kopf M, Otto M, Baier M. 2004. Role of interleukin-1 in prion diseaseassociated astrocyte activation. Am. J. Pathol. 165:671-678.
55. Caughey B, Lansbury PT. 2003. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26:267-298.
56. Collinge J, Palmer MS, Sidle KC, Gowland I, Medori R, Ironside J, Lantos P. 1995. Transmission of fatal familial insomnia to laboratory animals. Lancet 346:569-570.
57. Deshpande A, Mina E, Glabe C, Busciglio J. 2006. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci. 26:6011-6018.
58. Haass C, Selkoe DJ. 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8:101-112.
59. Hsiao KK, Scott M, Foster D, Groth DF, DeArmond SJ, Prusiner SB. 1990. Spontaneous neurodegeneration in transgenic mice with mutant prion protein. Science 250:1587-1590.
60. Medori R, Montagna P, Tritschler HJ, LeBlanc A, Cortelli P, Tinuper P, Lugaresi E, Gambetti P. 1992. Fatal familial insomnia: a second kindred with mutation of prion protein gene at codon 178. Neurology 42:669-670.
61. Hill AF, Collinge J. 2003. Subclinical prion infection in humans and animals. Br. Med. Bull. 66:161-170.
62. Hill AF, Joiner S, Linehan J, Desbruslais M, Lantos PL, Collinge J. 2000. Species-barrier-independent prion replication in apparently resistant species. Proc. Natl. Acad. Sci. U. S. A. 97:10248-10253.
63. Trevitt CR, Collinge J. 2006. A systematic review of prion therapeutics in experimental models. Brain 129:2241-2265.